Results
1 -
9 of
9
(Click
here to explore results)
- Successful Strategies for the Discovery of Antiviral Drugs, CHAPTER 1 Discovery and Clinical Validation of HCV Inhibitors Targeting the NS5A Protein. Makonen Belema, Nicholas A. Meanwell, John A. Bender, Omar D. Lopez, Piyasena Hewawasam, David R. Langley
, 2013
, Pages 3-28
- Phenotypic Drug Discovery, Chapter 1 Phenotypic Drug Discovery: History, Evolution, Future. David C. Swinney
, 2021
, Pages 1-19
- Successful Strategies for the Discovery of Antiviral Drugs, Subject index
, 2013
, Pages 509-534
- The Coronavirus Pandemic and the Future: Virology, Epidemiology, Translational Toxicology and Therapeutics, Volume 2, CHAPTER 1 In Silico Approaches for Drug Repurposing for SARS-CoV-2 Infection. Sudhir A. Kulkarni, Kundan Ingale
, 2022
, Volume 2
, Pages 1-80
- Macrocycles in Drug Discovery, CHAPTER 7 Linear and Macrocyclic Hepatitis C Virus Protease Inhibitors: Inhibitor Design and Macrocyclization Strategies for HCV Protease and Related Targets. Wieslaw M. Kazmierski, Richard L. Jarvest, Jacob J. Plattner, Xianfeng Li
, 2015
, Pages 235-282
- Antiviral Discovery for Highly Pathogenic Emerging Viruses, Chapter 1 Overview of Antiviral Drug Discovery and Development: Viral Versus Host Targets. Guangdi Li, Erik De Clercq
, 2022
, Pages 1-27
- The Medicinal Chemist's Guide to Solving ADMET Challenges, CHAPTER 3 Optimisation of Passive Permeability for Oral Absorption. Andy Pike, R. Ian Storer
, 2021
, Pages 36-61
- Phenotypic Drug Discovery, Subject Index
, 2021
, Pages 242-245
- The Coronavirus Pandemic and the Future: Virology, Epidemiology, Translational Toxicology and Therapeutics, Volume 1, CHAPTER 6 Therapeutic Options Initially Available for COVID-19 Patients and Initial Clinical Trials. Ssang-Goo Cho, Claude Hughes, Iyer Mahalaxmi, Mohana Devi Subramaniam, Balachandar Vellingiri, Stafford Warren
, 2022
, Volume 1
, Pages 136-164